Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesRisk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration
British Medical Journal, 08/21/09
Stone M et al. – Risk of suicidality associated with use of antidepressants is strongly age dependent. Compared with placebo, the increased risk for suicidality and suicidal behaviour among adults under 25 approaches that seen in children and adolescents. The net effect seems to be neutral on suicidal behaviour but possibly protective for suicidal ideation in adults aged 25–64 and to reduce the risk of both suicidality and suicidal behaviour in those aged >=65.
Related Articles
The Role of Sodium Channels in the Mechanism of Action of Antidepressants and Mood Stabilizers
Current Drug Targets, 10/30/09
Relevance Score: 87%
Increase In Long-term Antidepressant Drug Use, UK Study Reveals
ScienceDaily, 10/26/09
Relevance Score: 87%
Study reveals an increase in long-term antidepressant drug use
EurekAlert, 10/23/09
Relevance Score: 87%
Review: differences in efficacy and acceptability exist for 12 new-generation antidepressants for major depression
Evidence-Based Medicine, 10/26/09
Relevance Score: 84%
Diabetes incidence associated with depression and antidepressants in the Melbourne Longitudinal Studies on Healthy Ageing (MELSHA)
International Journal of Geriatric Psychiatry, 10/09/09
Relevance Score: 84%
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
A Clinical Review of Echinocandins in Pediatric Patients
Annals of Pharmacotherapy, 12/16/09
Sanofi Pasteur expands study of vaccine against Clostridium difficile into the U.S.
Sanofi-aventis, 12/16/09
Second Pivotal Phase III Study of Gileads Darusentan for Resistant Hypertension Misses Primary Endpoints
Gilead, 12/15/09
Sponsor
Article Search
Sponsor
Sponsor